Methylergometrinmaleat Zur Anwendung Bei Erwachsenen Frauen Panpharma

Methylergometrine maleate, the active ingredient in Methylergometrinmaleat Zur Anwendung Bei Erwachsenen Frauen Panpharma, is an ergot alkaloid presented as an injectable for intramuscular or intravenous use. It is employed to prevent and treat postpartum hemorrhage and uterine atony in adult women.

GNH USA supplies Methylergometrinmaleat Zur Anwendung Bei Erwachsenen Frauen Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Methylergometrine maleate is a uterotonic agent used in obstetric care to manage bleeding and uterine tone.

- Postpartum hemorrhage: promotes rapid uterine contraction to reduce blood loss. - Uterine atony: restores muscle tone when the uterus fails to contract after delivery. - Prevention of excessive bleeding: administered prophylactically during the third stage of labor to minimize hemorrhage risk.

Methylergometrine maleate may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: transient cranial discomfort. - Hypertension: temporary rise in blood pressure. - Flushing: reddening of the skin.

Serious or Rare Side Effects: - Coronary artery spasm: severe chest pain requiring immediate care. - Pulmonary edema: fluid accumulation in the lungs. - Uterine rupture: rare but life‑threatening tearing of the uterus. - Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty.

Use methylergometrine maleate with caution and under obstetric supervision.

- Blood pressure monitoring: check for hypertension before and after administration. - Cardiovascular disease: avoid in patients with known coronary artery disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Concomitant vasoconstrictors: avoid combining with other ergot derivatives. - Storage: Store at ambient temperature: keep in original container, protect from moisture and light.

Methylergometrine maleate can interact with several drug classes.

Major Interactions (Avoid): - Ergotamine or other ergot derivatives: additive vasoconstriction. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increased plasma levels.

Moderate Interactions (Monitor Closely):\n- Alpha‑adrenergic blockers: may blunt uterine contraction. - Calcium channel blockers: possible additive cardiovascular effects. - SSRIs: monitor for serotonergic excess.